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Abstract 
Background:  High‑frequency oscillatory ventilation (HFOV) has not been shown to be beneficial in the manage‑
ment of moderate‑to‑severe acute respiratory distress syndrome (ARDS). There is uncertainty about the actual pres‑
sure applied into the lung during HFOV. We therefore performed a study to compare the transpulmonary pressure (PL) 
during conventional mechanical ventilation (CMV) and different levels of mean airway pressure (mPaw) during HFOV.
Methods: This is a prospective randomized crossover study in a university teaching hospital. An esophageal balloon 
catheter was used to measure esophageal pressures (Pes) at end inspiration and end expiration and to calculate PL. 
Measurements were taken during ventilation with CMV (CMVpre) after which patients were switched to HFOV with 
three 1‑h different levels of mPaw set at +5, +10 and +15 cm H2O above the mean airway pressure measured during 
CMV. Patients were thereafter switched back to CMV (CMVpost).
Results: Ten patients with moderate‑to‑severe ARDS were included. We demonstrated a linear increase in Pes and 
PL with the increase in mPaw during HFOV. Contrary to CMV, PL was always positive during HFOV whatever the level 
of mPaw applied but not associated with improvement in oxygenation. We found significant correlations between 
mPaw and Pes.
Conclusion: HFOV with high level of mPaw increases transpulmonary pressures without improvement in 
oxygenation.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Moderate or severe acute respiratory distress syndrome 
(ARDS) [1] is associated with substantial mortality. Use 
of a lung-protective strategy with low tidal volume (Vt) 
of 6 ml/kg of predicted body weight has been associated 
with improved outcomes [2]. High-frequency oscillatory 
ventilation (HFOV) is a non-conventional mode which 
has been proposed to achieve the targets of protective 
ventilation with very low Vt [3] and a greater alveolar 
stability due to relatively constant mean airway pressure 
(mPaw) [4]. However, two large recently published ran-
domized clinical trials, OSCAR [5] and OSCILLATE 
[6], failed to prove any clinical benefit when HFOV was 
applied in adults with moderate-to-severe ARDS as com-
pared with a strategy with low tidal volume, high positive 
expiratory pressure (PEEP) and limited plateau pressure 
(Pplat). In the latter study, side effects of HFOV were 
observed with more requirements for vasopressors, likely 
due to right ventricular failure secondary to high mPaw 
used [7, 8].
Another possible explanation of the lack of clinical 
benefit with HFOV in adults with ARDS may be due to 
the occurrence of pulmonary overdistension in non-
dependant areas of the lung [9]. Because mPaw during 
HFOV does not reflect of the real pressure applied to the 
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alveoli [10], with non-predictable attenuation all along 
the trachea–bronchial tree, it is not possible to know the 
true pulmonary distending pressure. Esophageal pressure 
(Pes) is an approximation of the pleural pressure, and its 
use has shown a possible clinical benefit when PEEP was 
set according to the value of Pes in moderate-to-severe 
ARDS [11]. Esophageal pressure measurement allows the 
calculation of the maximal and minimal transpulmonary 
pressures (PL) applied during mechanical ventilation. 
Data reporting PL during HFOV are scarce [12] and only 
describe the feasibility of the technique but not the com-
parison of range of PL occurring during the switch from 
CMV to an HFOV trial. Therefore, we performed a pro-
spective study of PL determination in moderate-to-severe 
ARDS during and after an HFOV trial.
Methods
This is an ancillary study of a previously published study 
[7].
Patients
The study was approved by the ethics committee of the 
Marseille University Hospital (Comité de Protection des 
Personnes Sud Méditerranée, ID RCB:2008-A00077-48). 
Written informed consent was obtained from each 
patient’s next of kin. Patients admitted in the inten-
sive care unit of a university teaching hospital during a 
10-month period were screened if they met inclusion cri-
teria: moderate-to-severe ARDS with a PaO2/FiO2 ratio 
≤150  mmHg at a PEEP ≥8  cm  H2O. Exclusion criteria 
were age <18  years, moribund status, risks associated 
with HFOV (head injury, pneumothorax or a chest tube 
in place with persistent air leak) and contraindications to 
the placement of a nasogastric probe. All patients were 
sedated and continuously paralyzed [13]. The severity of 
illness was determined according to the Simplified Acute 
Physiologic II Score, the Sepsis-related Organ Failure 
Assessment Score and the Lung Injury Score [14, 15].
Tested ventilatory strategies
Patients were submitted to a 6-h period of CMV 
(CMVpre) in volume-controlled, constant square flow, 
mode using the AVEA ventilator (VIASYS Healthcare, 
Palm Springs, CA, USA) with a tidal volume of 6  mL/
kg of predicted body weight adjusted to obtain a pla-
teau pressure <30 cm H2O. PEEP and FiO2 were adjusted 
according to the ARMA protocol [2]. Patients were then 
switched to HFOV using a 3100B ventilator (Sensor-
Medics, Yorba Linda, CA, USA). After a recruitment 
maneuver was performed with a mPaw of 40  cm  H2O 
during 40  s with a pressure amplitude of oscillation of 
0 cm H2O [16], HFOV was set as follows: FiO2 as during 
the CMVpre period; frequency of 5 Hz; inspiratory time 
of 33 %; and bias flow of 40 L/min. The pressure ampli-
tude of oscillation and frequency were then adjusted to 
achieve a PaCO2 close to the PaCO2 measured during 
the CMVpre period. If pressure amplitude of oscillation 
of 110 cm H2O was insufficient to achieve a pH ≥ 7.25, 
frequency was decreased at 4 Hz. The protocol consisted 
of three 1-h periods of HFOV (HFO  +  5, HFO  +  10, 
HFO  +  15) in a randomized order, with a mPaw level 
calculated by adding 5, 10 or 15  cm  H2O to the mPaw 
measured during the CMVpre period (Fig. 1). A recruit-
ment maneuver was performed at the beginning of each 
HFOV period and before switch back to CMV. Res-
piratory frequency and pressure amplitude of oscilla-
tion were adjusted to maintain PaCO2 constant during 
the protocol. Measurements were taken at the end of 
each period of the protocol and 1  h after switch back 
to CMV. During the protocol, norepinephrine infusion 
was adjusted to maintain a mean arterial pressure above 
65 mmHg.
Esophageal and transpulmonary pressure measurements
A specific nasogastric feeding probe (SmartCath®, 
VIASYS Healthcare, Palm Springs, CA, USA) equipped 
with an esophageal balloon was inserted after in  vitro 
automatized test for leak search and compliance meas-
urement, and then the balloon was filled with a volume 
of air between 0.5 and 2  mL as recommended by the 
manufacturer. Every 30 min, the ventilator evacuates and 
refills the balloon to maintain measurement accuracy. 
The correct positioning in the lower third of the esopha-
gus was confirmed by the presence of cardiac artifacts, 
the changes in transpulmonary pressure during tidal 
ventilation and the parallelism of airway and esophageal 
curves after the interruption of a brief chest compres-
sion maneuver [17]. Finally, a chest X-ray excluded the 
misplacement of the probe into the airway. Esophageal 
pressures were recorded and monitored by the integrated 
system, CP-100 pulmonary monitor (Bicore Monitor-
ing System Inc®, Irvine, CA, USA) present in the AVEA 
ventilator. An end-inspiratory occlusion of 2  s allowed 
the measurement of, respectively, Pplat and inspiratory 
Pes (Pesinsp), whereas an end-expiratory occlusion of 5 s 
allowed the measurement of, respectively, total PEEP 
(PEEPtot) and expiratory Pes (Pesexp) during CMV. Dur-
ing HFOV periods, because interruption of ventilation is 
not possible, screen of the AVEA ventilator was frozen 
for measuring the peak and trough amplitude of oscilla-
tions for measurements of, respectively, the maximum 
and minimum Pes. The following formulas were com-
puted as follows:
PEEPtot = external PEEP+ intrinsic PEEP
Driving pressure = Pplat− PEEPtot
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During CMV,
During HFOV,
An example of tracings in the two ventilatory modes 
with the airway, esophageal and transpulmonary pres-
sures determinations and calculations is provided in 
Fig. 2.
Statistical analysis
Data are presented as mean ± SD or median (interquar-
tile range) as required. Normality of variables was tested 
according the Kolmogorov–Smirnov test. Repeated-
measures analysis of variance or Friedman’s test was used 
to evaluate the effect of time and mPaw level. The Tukey 
test or the Wilcoxon test was used for intergroup com-
parisons. Bivariate correlations with Spearman’s test for 
each period of ventilation were performed. All statistics 
and figures were performed with the SPSS 20.0 package 
(SPSS, Chicago, IL, USA).
Results
Among the 16 patients included in the princeps study [7], 
ten patients were monitored by the esophageal catheter 
and were used in this study.
PLinsp = Pplat− Pesinsp
PLexp = PEEPtot − Pesexp





Chest wall elastance (ELCW) = (Pesinsp − Pesexp)/Vt
Pulmonary elastance (ELL) = ELRS − ELCW = (PLmax − PLmin)/Vt
Pesmean = (Pesmax + Pesmin)/2
PLmean = mPaw− Pesmean
Table  1 reports patient’s characteristics at inclusion. 
Initial computed tomography scan or thoracic radiograph 
showed five lobar and five diffuse presentations. Causes 
of ARDS were bacterial pneumonia (n = 4), influenza A 
(H1N1), (n =  2), aspiration (n =  2), post-cardiopulmo-
nary resuscitation (CPR) (n =  1) and acute pancreatitis 
(n  =  1). Fluid loading was performed in three patients 
during the CMVpre period. At baseline, all except one 
received norepinephrine infusion to maintain mean arte-
rial pressure (MAP) above 65 mmHg.
Respiratory parameters
During HFOV, mPaw was progressively increased from 
18 ± 4 cm H2O in CMVpre period to 33 ± 4 cm H2O at 
HFO + 15 (Table 2). PaO2/FiO2 ratio did not significantly 
change under HFOV when compared with the CMVpre 
period. However, it increased by more than 20 % in three 
patients at HFO + 5, in four patients at HFO + 10 and in 
two patients at HFO + 15. FiO2 was slightly lower at the 
end of the study. Worsening of oxygenation occurred in 
two patients at HFO + 5, in three patients at HFO + 10 
and in four patients at HFO  +  15. As required by the 
protocol, PaCO2 and pH were kept constant through-
out the study. Concerning respiratory mechanics, Pplat, 
driving pressure, respiratory system elastance, chest wall 
elastance and pulmonary elastance were similar during 
the CMVpre and CMVpost periods. These last param-
eters could not be calculated during the HFOV periods 
because of the lack of tidal volume monitoring.
At similar level of mPaw, during the volumetric peri-
ods of ventilation (CMVpre and CMV post), we did not 
find differences concerning esophageal and transpulmo-
nary pressures. During HFOV periods, we observed a 
Fig. 1 Study design
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linear increase in esophageal pressure from 12.4 [10.6; 
16.7] to 19.1 [16.7; 23.3] cm of H2O (p = 0.001) as mPaw 
increases from 23 ±  4 to 33 ±  4 cm of H2O. As a con-
sequence, mean PL increased during HFOV periods from 
10.5 [7.3; 13.8] to 14 [11.5; 16.3] cm of H2O (Table  2; 
Fig. 3). Interestingly, there was no negative transpulmo-
nary pressure whatever the period of HFOV ventilation. 
There were, however, seven (out of ten) patients with 
negative minimal PL during the CMVpre period and only 
three (out of ten) patients during the CMVpost period 
(p = 0.07, χ2 test).
During HFO, mPaw was correlated with Pesmean at 
HFO + 5 and HFO +15 periods (respectively, ρ = 0.71, 
p  =  0.02 and ρ  =  0.84, p  =  0.02) but at no time with 
PLmean.
Discussion
The present study assessing the use of esophageal pres-
sure measurements in patient with moderate-to-severe 
ARDS on whom a trial of HFOV is performed demon-
strates (1) a linear increase in transpulmonary pressures 
with the increase in mPaw during HFOV, (2) a minimal 
transpulmonary pressure which was always >0 during 
HFOV and (3) a correlation between mean esophageal 
pressure and mPaw.
For decades, HFOV has been used for respiratory fail-
ure in both adults and children who were inadequately 
responsive to conventional mechanical ventilation. How-
ever, recently the results of the OSCAR [5] and OSCIL-
LATE [6] studies performed on adults have not shown 
benefit to HFOV over conventional ventilation. A recent 
study in the pediatric population has also shown equivo-
cal results with HFOV [18]. Indeed, positive studies on 
HFOV are limited [16, 19] and predate the era of low 
tidal volume conventional mechanical ventilation. Dur-
ing HFOV, there is uncertainty about the real pressure 
that is applied to the alveoli and therefore the distend-
ing pressure applied into the lung. Henderson et al. [12] 
have previously described the use of esophageal manom-
etry to measure PL during HFOV. With a mean airway 
pressure of 27  ±  5  cm  H2O during HFOV, they meas-
ured a mean esophageal pressure of 14 ± 4 cm H2O and 
computed a mean PL of 18 ± 4 cm H2O. These data are 
Fig. 2 Representative tracings of mean airway pressure (mPaw), plateau pressure (Pplat), total positive expiratory pressure (PEEPtot), esophageal 
pressure (Pes) and transpulmonary pressure (PL) during conventional mechanical ventilation (CMV) and high‑frequency oscillatory ventilation
Table 1 Patient characteristics and  respiratory data 
at inclusion
Oxygenation index was calculated as mean airway pressure × FiO2 × 100)/PaO2. 
Results are provided as mean ± SD
FiO2, inspired oxygen fraction; PEEP, positive end-expiratory pressure; mPaw, 
mean airway pressure; IPBW, ideal predicted body weight; SAPS II, Simplified 
Acute Physiology Score II; SOFA, Sepsis Organ Failure Assessment Score; Vt, tidal 
volume
Age (years) 63 ± 15
Gender (male), n (%) 4 (40)
Body mass index (kg/m2) 29 ± 8
SAPS II at the admission 49 ± 23
SOFA at the admission 11 ± 3
ICU mortality, n (%) 4(40)
Direct lung injury, n (%) 9 (90)
CT scan or X‑ray presentation (lobar/diffuse), n 5/5
PaO2/FiO2 ratio (mmHg) 131 ± 51
FiO2 0.74 ± 0.17
PaCO2 (mmHg) 46 ± 7
PEEP (cm H2O) 13 ± 3
Vt (mL)/(mL/kg/IPBW) 382 ± 41/6.6 ± 0.7
Respiratory rate (cycle/min) 26 ± 4
Plateau airway pressure (cm H2O) 24 ± 4
Driving pressure (cm H2O) 12 ± 3
mPaw (cm H2O) 18 ± 3
Oxygenation index 17 ± 9
Lung Injury Score at the inclusion 3.0 ± 0.5
Time from ARDS to inclusion (d) 0 ± 0.5
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Table 2 Gas exchanges and respiratory mechanics
PL transpulmonary pressure, NA not applicable
p values in italic are provided for < 0.05
a p < .05 vs. HFO + 5, b p < .05 vs. HFO + 10, c p < .05 vs. HFO + 15, d p < .05 vs. CMVpre, e p < .05 vs. CMVpost
CMVpre HFO + 5 HFO + 10 HFO + 15 CMVpost p value time
mPaw (cm of H2O) 18 ± 4a,b,c 23 ± 4b,c,d,e 28 ± 4a,c,d,e 33 ± 4a,b,d,e 17 ± 4a,b,c <0.001
PaO2/inspired O2 fraction (mmHg) 131 ± 51 132 ± 56 125 ± 23 138 ± 49 139 ± 34 0.9
Inspired O2 fraction 74 ± 17 71 ± 16 72 ± 16 77 ± 18 67 ± 10d 0.03
Arterial pH 7.29 ± 0.04 7.31 ± 0.09 7.31 ± 0.01 7.29 ± 0.1 7.32 ± 0.06 0.3
PaCO2 (mmHg) 46 ± 7 47 ± 12 46 ± 14 46 ± 9 42 ± 7 0.5
PEEP (cm of H2O) 13 ± 3 NA NA NA 12 ± 3 0.4
Vt (ml/kg) 6.6 ± 0.7 NA NA NA 6.7 ± 0.8 0.2
Plateau airway pressure (cm of H2O) 24.5 ± 4 NA NA NA 23.5 ± 4 0.06
Driving pressure (cm of H2O) 11.8 ± 3.4 NA NA NA 11.5 ± 3.3 0.4
Power of oscillations, % NA 73 ± 23 79 ± 29 81 ± 24 NA 0.1
Respiratory rate (cycle/min) 26 ± 4 NA NA NA 25 ± 6 1
Oscillatory frequency (Hz) NA 4.8 ± 1 4.7 ± 0.7 4.6 ± 1 NA 0.2
Inspiratory esophageal pressure 15 [11.5; 21.2] NA NA NA 14 [10.2; 17.2] 0.1
Expiratory esophageal pressure 12.5 [5.1; 13.5] NA NA NA 9.1 [5.4; 13.5] 0.1
Mean esophageal pressure (cm of 
H2O)
NA 12.4 [10.6; 16.7]b,c 16.7 [12.5; 18.7]a,c 19.1 [16.7; 23.3]a,b NA 0.001
Inspiratory PL (cm of H2O) 8.1 [5.7; 12.8] NA NA NA 11.8 [5; 12.1] 1
Expiratory PL (cm of H2O) −1 [−3; + 0.7) NA NA NA +3.5 [−3; + 6] 0.2
Mean PL (cm of H2O) NA 10.5 [7.3; 13.8]
c 13.1 [9.2; 14.7] 14 [11.5; 16.3]a NA 0.001
Respiratory system elastance (cm of 
H2O/L)
31.2 ± 9.7 NA NA NA 29.9 ± 8 0.2
Chest wall elastance (cm of H2O/L) 15.7 ± 6 NA NA NA 11.1 ± 4.5 0.3
Pulmonary elastance (cm of H2O/L) 15.9. ± 11 NA NA NA 18.9 ± 6 0.3
Fig. 3 Airway pressures, esophageal pressures and transpulmonary pressures (PL) during conventional mechanical ventilation (CMV) before and 
after three levels of mean airway pressure (mPaw) during high‑frequency oscillatory ventilation (HFO). Airway pressure is plateau pressure (Pplat) 
during CMV and mPaw during HFO. Esophageal pressure is the inspiratory pressure during CMV and the mean esophageal pressure during HFO. PL 
is computed by Pplat minus inspiratory esophageal pressure during CMV and mPaw minus mean esophageal pressure during HFO. *Means < 0.05
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consistent with the present results, namely a mPaw of 
28 ±  4  cm  H2O, results in a median of 16.7 IQR [12.5; 
18.7]  cm  H2O range of Pes and a median of 13.1 IQR 
[9.2; 14.7] cm H2O range of PL. The safe range of PL dur-
ing HFO is not known. However, during conventional 
mechanical ventilation for ARDS, a PL  >  27  cm  H2O is 
associated with an unacceptably high level of strain [20]. 
The PL value recorded during HFO remains below this 
threshold whatever the level of mPaw.
One interesting result is the correlation between mPaw 
and esophageal pressure that we obtained; the more 
mPaw is set, the more Pes is measured. In clinical prac-
tice, levels of mPaw in the OSCAR and OSCILLATE 
trials [5, 6] were not exactly the same. During the first 
2 days of the studies, mPaw was set at 5 cm H2O higher 
in the Canadian trial than in the UK trial. These differ-
ences could have led to more pulmonary overdistension 
and side effects that could explain the deleterious out-
comes observed with HFOV in the OSCILLATE trial.
An ongoing study, the EPOCH study [21], which aim 
is to compare a strategy of preventing atelectrauma with 
a PL of 0 cm H2O at end expiration to a strategy of lung 
recruitment to target PL of 15 cm H2O at end-inspiratory 
volume in a crossover design either with CMV and either 
with HFOV will clarify the protective or deleterious roles 
of HFOV as compared to CMV.
Limitations
First, as measurements of esophageal pressure could 
not be taken in static conditions during HFO periods, 
we cannot rule out a possible bias of measurements due 
to cardiac artifacts. However, the use of mean esopha-
geal pressure reduces this bias. Second, during HFOV, 
due to the lack of Vt monitoring, we use the calcula-
tion of PL derived from Pes measurements [22] and not 
the elastance-derived measurements of PL [23] which 
could lead to different results [24]. Indeed, experimen-
tal data have shown that although recorded value of Pes 
is a quite accurate approximation of measured pleural 
pressure in the middle part of the lungs, Pes can over-
estimate or underestimate the value of pleural pressure 
whether in the non-dependant part and whether in the 
dependant part of the lungs [25]. The more convinc-
ing results are that the variations of Peso reflect those 
in pleural pressure whatever the parts of the lung [26]. 
There is still a matter of controversy on the use of the 
former or the latter method. A prospective ongoing 
study could bring a response to the clinical utility of 
the method used [27]. Third, because we have not per-
formed the registration of airway pressure during HFO, 
we cannot exclude negative PL during the active expira-
tory phase, and further studies are needed to conclude. 
And fourth, from a technical point of view, we also 
cannot exclude that larger inflation volume as dem-
onstrated by Mojoli et al. [28] could have led to differ-
ent results. However, our study precedes the one from 
Mojoli, and we used the volume and the proceeding rec-
ommended by the manufacturer.
We cannot speculate whether lower mPaw during 
HFOV, the same range as recorded in CMV, could lead to 
lower esophageal and transpulmonary pressures recorded. 
A level of <+10 cm H2O of mPaw during HFO does not 
increase significantly Peso and PL. Only a level of ≥+15 
cm H2O of mPaw increases significantly both Peso and PL.
Conclusion
The use of high mean airway pressures during HFOV 
leads to increase in transpulmonary pressures. Con-
trary to CMV, during HFOV, transpulmonary pressure 
remains always positive.
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